AMENDED CLAIM SET:

- 1. (Currently amended) A peptide comprising a portion of a protein selected from the group consisting of plasminogen, endostatin, VEGF, FLT-1 and KDR/FLK-1, wherein said peptide is of length from 7-20 amino acids long and wherein said peptide exhibits an IC₅₀ of 20 μ M or less in a bovine aorta endothelial cell proliferation assay or exhibits inhibition of angiogenesis in a chick chorioallantoic membrane assay of at least 30% at a dose of 50 μ g/coverslip.
- 2. (Original) The peptide of claim 1 that exhibits an IC₅₀ of 20 nM to 20 mM in a bovine aorta endothelial cell assay or exhibits inhibition of angiogenesis in a chick chorioallantoic membrane assay of at least 50% at a dose of 10 to 25 $\mu g/coverslip$.
- 3. (Original) The peptide of claim 1 comprising a portion of a kringle domain of plasminogen.
- 4. (Original) The peptide of claim 3, wherein said portion of a kringle domain is represented by residues 27-41 of a kringle domain of human or mouse plasminogen.

- 5. (Original) The peptide of claim 3, wherein said portion of a kringle domain is represented by residues 29-38 or residues 29-39 of a plasminogen.
- 6. (Original) The peptide of claim 1 that lacks any cysteine or if it contains any cysteine, the cysteine is blocked to prevent disulfide formation.
- 7. (Currently amended) The peptide of claim 1 that is derived from endostatin, VEGF, FLT 1 and KDR/FLK-1 and has a length of from 9 to 20 amino acids long.
- 8. (Original) The peptide of claim 7 that lacks any cysteine or if it contains any cysteine, the cysteine is blocked to prevent disulfide formation.
- 9. (Currently amended) The peptide of claim 1, comprising a peptide having an amino acid sequence selected from the group consisting of SEQ. ID. NOS. SEQ ID NOS 1-3, 11-33, 35 38, 40 41 and 44-50 35, and 47-50.
- 10. (Currently amended) The peptide of claim 1, comprising a peptide having an amino acid sequence selected from the group consisting of SEQ. ID. NOS. SEQ ID NOS 1-3, 11, 12, 29-36 and 38-39 and 29-35.

- 11. (Cancelled).
- 12. (Cancelled).
- ${f 13.}$ (Original) A pharmaceutical composition comprising a peptide according to claim ${f 1}$ and a pharmaceutically acceptable carrier.
- 14. (Original) The composition according to claim 13, wherein said composition provides a unit dose of from 20 $\mu g/kg/day$ to 2 mg/kg/day.
- 15. (Currently amended) A pharmaceutical composition comprising a peptide according to claim $\underline{10}$ $\underline{11}$ and a pharmaceutically acceptable carrier.
- 16. (Original) The composition according to claim 15, wherein said composition provides a unit dose of from 20 $\mu g/kg/day$ to 2 mg/kg/day.
 - 17. (Cancelled).
 - 18. (Cancelled).
- 19. (Original) A method for preventing or treating undesired angiogenesis comprising administering to a subject at risk for or

presenting undesired angiogenesis an effective amount of the composition of claim 13 to a subject.

20. (Original) A method for preventing or treating undesired angiogenesis comprising administering to a subject at risk for or presenting undesired angiogenesis an effective amount of the composition of claim 15 to a subject.

21. (Cancelled).

- 22. (Currently amended) A method for preventing or treating primary tumor growth or metastasis by preventing undesired angiogenesis, said method comprising administering to a subject at risk for or presenting a tumor an effective amount of the composition of claim 13.
- 23. (Currently amended) A method for preventing or treating primary tumor growth or metastasis by preventing undesired angiogenesis, said method comprising administering the composition of claim 15 to a subject at risk for or presenting a tumor.

24. (Cancelled).

25. (New) The peptide of claim 1, comprising the peptide having the amino acid sequence of SEQ ID NO:30.

- 26. (New) A pharmaceutical composition comprising the peptide according to claim 25 and a pharmaceutically acceptable carrier.
- 27. (New) A method for preventing or treating undesired angiogenesis comprising administering to a subject at risk for or presenting undesired angiogenesis an effective amount of the composition of claim 26 to a subject.
- 28. (New) A method for preventing or treating primary tumor growth or metastasis by preventing undesired angiogenesis, said method comprising administering to a subject at risk for or presenting a tumor an effective amount of the composition of claim 25.